Study of Tear Protein Changes in Dry Eye and Meibomian Gland Dysfunction Before and After Low Level Light Therapy in Adults 21 and Older

What this Trial Is About

This research aims to understand how low-level light therapy works and to identify markers linked to good treatment responses in people with dry eye disease and meibomian gland dysfunction. The therapy uses a specialized eye-light device that delivers light energy to the meibomian gland cells to slow aging, improve tear stability, and reduce inflammation. The study is observational and focuses on the changes in tear proteins before and after treatment. Participants will undergo low-level light therapy using an advanced eye-light device. The therapy is delivered through this device to target the meibomian glands. The study compares tear proteomics profiles at the start and after approximately three months following treatment. There are no additional treatment arms or placebo groups since this is an observational study. During the study, participants will have their tear proteins analyzed at the baseline visit and again three months later. Researchers will monitor changes in tear proteomics to assess treatment effects. Participants must be able to give informed consent and meet other eligibility requirements. The total duration of involvement includes the baseline and post-treatment assessments around three months apart.

Comparing Tear Proteomics Profile in Dry Eye Disease pre-and Post-treatment With Low Level Light Therapy